after joining the study, the patient undergoes an initial clinical evaluation that records medical history and the severity of atopic dermatitis (also known as eczema).

the evaluation includes physical measurements of the skin condition and documentation of any current symptoms.

the patient receives a single dose of the study medication, which is either lebrikizumab or a matching placebo, provided as a solution for injection in a pre‑filled syringe.

the injection is given subcutaneously (under the skin) by a healthcare professional at the study site.

the exact dose amount is not specified in the available information.

the patient returns to the clinic at regular intervals defined by the study protocol to receive additional injections of the study medication.

each visit includes safety monitoring, a physical examination, assessment of the skin condition, and recording of any adverse events (undesired side effects).

the frequency of these visits is not detailed in the provided data.

the patient continues to receive the assigned study medication for the duration of the long‑term extension phase, which may extend for several years.

the overall study period runs from december 2023 to april 2029, allowing observation of long‑term safety and efficacy.

at the conclusion of the study period, the patient undergoes a final evaluation that includes comprehensive safety assessments.

the final visit documents any discontinuation of the study medication due to adverse events and records the overall outcome of the trial.